The FDA accepts Regeneron Pharmaceuticals ' ( REGN ) sBLA for Eylea in DME. PDUFA date: 08/18/2014 Submission based on VIVID and VISTA. ( PR ) Post your comment!
Regeneron Pharmaceuticals , Inc. ( REGN ) Oppenheimer & Co. Inc. 24th Annual Healthcare Conference ..... the biotech analysts here. Very happy to have with us Regeneron Pharmaceuticals and speaking from Regeneron is Michael Aberman, Head
play for phones, Skyworks is the one to buy." Micron ( MU ): "If you want a component parts maker for PCs, Micron is the one." Regeneron ( REGN ): "It is a wild trader. I think the future is bright for Regeneron. Complete Story »
By Pharma Intelligence : Investment Thesis Ophthotech ( OPHT ) lead drug candidate Fovista currently in Phase 3 trials may be the first disease modifying drug for the treatment of wet AMD to reach the market. In the Phase 2b study, Fovista when added to Roche's ( OTCQX:RHHBY ) Lucentis was able to
By The Swiss Trader : Over a five-year period of time, only Pharmacyclics ( PCYC ) has performed better than Jazz Pharmaceuticals ( JAZZ ). Yet, despite Jazz's five-year 8,000% return, the stock rarely finds itself in the headlines or even widely covered by analysts. In 2013, Jazz has more than ...
Regeneron Pharmaceuticals , Inc. ( REGN ) Piper Jaffray Healthcare Conference December 03, 2013 ..... http://seekingalpha.com/article/1874331- regeneron - pharmaceuticals -management-presents-at-piper-jaffray-healthcare
By Scott Matusow : Written by Scott Matusow pSivida ( PSDV ) has been on our radar for over one year now, as we first wrote about the company in April of 2012 detailing the company's good long-term prospects. When it comes to small cap companies, the first thing we look for is strong leadership. ...
Regeneron Pharmaceuticals , Inc. ( REGN ) Deutsche Bank 2013 BioFEST ..... very excited next to have Regeneron Pharmaceuticals . And with us from Regeneron ..... article/1872551- regeneron - pharmaceuticals -ceo-presents-at
Bayer ( OTCPK:BAYZF ) has filed a request in Japan to use Regeneron's ( REGN ) Eylea to treat Myopic Choroidal Neovascularization (myopic CNV), a common cause of blindness in the country. Eylea is already
dramatically outperformed the broader market over the past two years. Some firms held in this ETF, such as Regeneron Pharmaceuticals REGN , Biogen BIIB, Celgene CELG, Gilead Sciences GILD, and Amgen AMGN, have led the rally, benefiting from